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Abstract: The hemolytic uremic syndrome (HUS) caused by Shiga toxin-producing Escherichia coli (STEC) is one of  
the most frequent causes of pediatric acute renal failure. The aim of this study was to report the clinic and microbiologic 
features associated with 13 post-diarrheal HUS cases identified in pediatric intensive care units in the city of São Paulo, 
Brazil, from January 2001 to August 2005. Epidemiologic, clinic, and laboratorial information, along with fecal and  
serum samples, were collected for identifying the genetic sequences of Stx and for studying antibodies directed against 
LPS O26, O111 and O157. STEC was isolated from three patients, and serotypes O26:H11, O157:H7 and O165:H
- were 
identified. In nine patients, high levels of IgM against LPS O111 (n=2) and O157 (n=7) were detected. Dialysis was  
required in 76.9% of the patients; arterial hypertension was present in 61.5%, neurological complications were observed 
in 30.7%, and only one patient died. During a 5–year follow-up period, one patient developed chronic kidney disease. The 
combined use of microbiologic and serologic techniques provided evidence of STEC infection in 92.3% of the HUS cases 
studied, and the importance of O157 STEC as agents of HUS in São Paulo has not been previously highlighted. 
Keywords: Hemolytic Uremic Syndrome, pediatric intensive care unit, diarrhea, Shiga toxin, E. coli O157, dialysis, children. 
INTRODUCTION 
  Hemolytic Uremic Syndrome (HUS), a life-threatening 
human illness, has been associated with Shiga toxin-
producing Escherichia coli (STEC) infections, particularly in 
children [1]. Although serotype O157:H7 was the first to be 
associated with enterohemorrhagic disease and represent 
most of the STEC strains related to large outbreaks and se-
vere disease, a number of other non-O157 serotypes has been 
equally associated with the occurrence of HUS [2]. Produc-
tion of Shiga toxins (Stx1 and Stx2) is a key step in the viru-
lence mechanism of STEC, believed to be the most impor-
tant event towards HUS development [3]. However, pres-
ence of other virulence factors like a hemolysin called en-
terohemorrhagic  E. coli (EHEC) hemolysin (Ehx) and the 
intimin protein, present in strains that harbor the eae gene, 
can also contribute to STEC pathogenesis [4]. Infections due 
to STEC have a proven zoonotic character, being ruminant 
animals, especially cattle, the most important natural reser-
voir [5]. Therefore, transmission of STEC to humans oc-
curred mainly via the food chain or by direct contact with the 
animals or their environment, but person-to-person transmis-
sion, although less common, has also been reported [6,7]. 
  In Brazil, efforts have been made to establish a national 
surveillance system for HUS but there are still little or no  
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data available. However, in other Latin America countries as 
Argentina, HUS is the main cause of acute kidney disease 
and the second most predominant cause of chronic kidney 
disease in children under the age of five years, and responsi-
ble for more than 15% of kidney transplants in children and 
adolescents [8]. 
  In 2001, we started a surveillance study on post-diarrheal 
HUS in São Paulo city, Brazil, to investigate the association 
of this syndrome with STEC infections. This study describes 
the results of the microbiologic and serologic investigation 
of cases admitted in pediatric intensive care units (PICU), 
and their evolution, prognosis and mortality. 
MATERIALS AND METHODS 
  This was a prospective clinical, observational, multicen-
ter, non-controlled and non-randomized study, performed 
from 2001 to 2005. The required information was disclosed 
by the Department of Intensive Care and the Pediatric Soci-
ety in São Paulo, and pediatric intensive care physicians and 
nephrologists were asked to communicate the cases admitted 
to their units. The study was approved by the Research Eth-
ics Committee at the Universidade Federal de São Paulo 
(UNIFESP), and parents gave informed consent for their 
children to be included in the study. The criteria for enroll-
ment included children hospitalized in the PICU with an 
acute case of hemolytic microangiopathic anemia, kidney 
failure and thrombocytopenia, which was preceded by   
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anemia with hemoglobin < 10.5 g/dl, with or without   
evidence of erythrocyte fragmentation; thrombocytopenia 
with < 75,000 /mm
3; and acute kidney failure with creatinine  
levels over the upper limit for the age.  
  Personal and demographic data, as well as information 
regarding onset and type of diarrhea, previous use of antibi-
otics, cases of diarrhea in the family or closely related peo-
ple, eating habits, ingestion of undercooked meat or of non-
pasteurized foods and contact with animals were collected. 
Clinical and laboratory monitoring was performed during the 
hospitalization from 2001 to 2005. Information about the 
long-term effects of the disease was obtained through contact 
with the parents and/or nephrologists who accompanied the 
patients. Data were collected until 2007. 
Isolation and Identification of STEC 
  Fecal samples were collected as soon as HUS was   
suspected and plated onto Sorbitol-MacConkey agar and 
incubated at 37
oC for 18 hours. Sorbitol fermenting and   
non-fermenting E. coli isolates were tested for stx1 and stx2 
by polymerase chain reactions (PCR) [9]. The stx positive 
isolates were serotyped by standard procedures using O (O1 
– O181) and H (H1-H56) antisera kindly provided by the 
Centers for Diseases Control and Prevention (CDC, USA) 
[10]. STEC isolates were further tested for the presence of 
intimin (eae) and enterohemolysin (ehxA) gene sequences by 
PCR as previously described [11,12]. To verify the expres-
sion of Stx toxins, filtrates from E. coli positive culture   
samples used in the PCR trials were prepared and inoculated 
into HeLa and Vero cell monolayers, [13].  
Detection of LPS Antibodies 
  Presence of IgM and IgG classes of antibody against LPS  
O26, O111 and O157 was searched for by enzyme-linked   
immunosorbent (ELISA) assays in serum samples collected  
from all patients except one, at admission or as soon as HUS  
was diagnosed (acute phase) using the methods described   
[14,15]. In brief, PolySorp ELISA plates (NUNC, Naperville,  
III., USA) were coated with 10 μg/ml of E. coli LPS O26  
and O111, purchased from Sigma (Sigma Chemical Co. - St.  
Louis, MO, USA), and LPS O157 (List Biological Laboratories,  
Inc - California, USA). Sera samples were diluted 1:500 in  
Phosphate-buffered saline (PBS) containing 0.05% Tween   
20 and incubated for 2 hours at room temperature. Presence  
of IgM and IgG antibodies was investigated in the samples  
by using anti-human IgM and IgG conjugated peroxidase   
(Sigma) diluted 1:1000 and incubated for 2 hours at   
room temperature. Reaction was developed with 10 mg of o- 
phenylenediamine in citrate buffer pH 4.5 containing 0.012%  
H2O2, and absorbance values were measured at 492 nm   
(A492). Positive sera controls were included in all ELISA   
assays and were obtained from patients who had HUS in   
association with STEC O26 and O157 infections (kind gift  
from Dr. Alfredo Caprioli, Istituto Superiore di Sanità,   
Rome, Italy). The O111 positive control serum was obtained  
at the beginning of this study. 
  One sera sample obtained from 63 children without   
gastrointestinal symptoms and infection who had visited the  
outpatient clinic of the São Paulo Hospital from August to  
September of 2004 were used to evaluate the presence of   
antibodies against LPS O26, O111 and O157 in the general  
population. All sera were diluted 1:500 in PBS-Tween, and  
the cutoff value was defined as the average of the IgM   
or IgG values in the sera plus three times the value of the  
standard deviation. 
  To confirm the specifity of the ELISA results, LPS im-
munoblotting was performed as described by Chart et al. 
[16] using patients sera diluted 1:100, and bound immuno-
globulin was detected using anti-human polyvalent immuno-
globulins conjugated peroxidase (Sigma Chemical Co.) di-
luted 1:2000 and the reaction was developed using chemilu-
minescent detection system (ECL, Amersham Biosciences, 
Sweden).  
RESULTS 
1. Epidemiology 
  Thirteen cases fulfilled the diagnostic criteria and there 
was no refusal to participate in the study. Ten patients (77%) 
came from private hospitals and three (23%) from public 
hospitals. Ages ranged from 8 months to 6 years and 3 
months, with a mean of 2 years and 5 months. However, 
almost half of the patients (46%) were less than 2 years old. 
Eight patients (61.5%) were female. The seasonal distribu-
tion of the cases was as follows: six cases in the Summer, 
three in the Winter, three in the Spring and one in the Fall. 
All children had diarrhea, 69.2% with blood or mucus, and 
with diarrheal prodroms for a median of 6.4 days (Table 1). 
There were no reports of diarrhea or gastroenteritis among 
family members or people in close contact with the patients. 
A positive response to the ingestion of undercooked or non-
pasteurized food, or contact with animals (specifically bo-
vines) occurred in 69.2% of patients (Table 1). 
2. Isolation and Identification of STEC 
  STEC was isolated from three out of seven patients 
whose stool cultures yielded bacterial growth, and serotypes 
O26:H11, O157:H7 and O165:HNM were identified (Table 
1). Except for the O26:H11 strain that harbored stx1  eae 
ehxA, the other STEC isolates presented the stx2 stx2c eae 
ehxA genotype. Expression of Stx was identified in all STEC 
isolates. 
3. LPS Antibodies 
  Low levels of antibodies to LPS O26, O111 and O157 
were identified in sera of children with no gastrointestinal 
disorders (control population), with cutoff values (Cv)  0.5, 
except for O111 IgG responses that presented variations, 
generating a Cv =1.095 (Table 2, Fig. 1-3). In contrast, 
higher levels of O111 LPS antibodies (IgM and IgG) were 
identified in sera of 2 out of 12 HUS patients (Table 1, Fig. 
2), and increased levels of IgM to LPS O157 were detected 
in sera from 7 patients (Table 1, Fig. 3). In five of these 
seven patients, high levels of IgG were also identified. These 
levels of antibodies were much higher than the cuttoff values 
observed in the group of children with no diarrhea (Table 2, 
Figs. 2,3), even when higher serum dilutions (1:1000) were 
analyzed (data not shown). ELISA results were confirmed by 
specific O157 and O111 LPS recognition in HUS patient’s 
sera by immunoblotting analysis (Fig. 4). Serum samples 
taken approximately 15 days after hospital admission (con-
valescence) were available for ELISA analysis from 7 of the 78    The Open Microbiology Journal, 2011, Volume 5  de Souza et al. 
9 HUS patients that presented O111 (n=1) or O157 (n=6) 
LPS antibodies response. All these sera presented a de-
creased in IgM levels compared to the acute phase sera, but 
in five patients the IgM and IgG levels were still higher than 
the cuttoff values (data not shown).  
4. Clinical and Laboratory Data 
  The clinical and laboratory characteristics of HUS cases 
are shown in Table 3. The average hemoglobin value was 8.2 
g/dl, and the lowest limit for platelets was 15,000/mm
3. 
Changes in kidney function showed average creatinine val-
ues of 3.27 mg/dl, and average urea values of 132 mg/dl. 
Four patients (30%) showed the presence of schistocytes. 
Normalization of the platelet count occurred in 76% of the 
patients two weeks after the onset of the disease. Only 38% 
of the patients exhibited normalization of creatinine levels in 
the first two weeks of the disease, and two patients (15%) 
exhibited oliguria for a period of more than 15 days. Arterial 
hypertension was observed in eight patients (61.5%), and 
involvement of the central nervous system was seen in four 
(30.7%); changes in other organs or systems were not ob-
served. Renal replacement therapy with peritoneal dialysis in 
the first 24 hours of admission to the PICU was necessary in 
10 (76.9%) patients, with an average time of dialysis of 12 
days (range: 6–38 days). The average length of stay in PICU 
was 16 days, and the average duration of hospitalization was 
24 days. The only patient who died exhibited severe arterial 
hypertension that was difficult to control, bleeding and neu-
rological involvement; anti-LPS O111, IgM (0.775) and IgG 
(3.200) antibodies were also detected. During the 2 to 5 
years following hospitalization, a questionnaire was sent to 
the parents or nephrologists who had accompanied the chil-
dren. From this, we found that only one patient (1/10) had 
developed chronic kidney disease without hypertension or 
the need for dialysis after discharge, but had persistent prote-
inuria. Two patients presented neurological sequelae, one of 
them with paresis of the lower left limb from a hemorrhagic 
Table 1.  Epidemiologic, Microbiologic and Serologic Characteristics of HUS Patients 
Case Season  Sex
a Age  Prodromes  Bloody   
Diarrhea 
Source of  
Contamination
b 
STEC  
Isolation 
-LPS            -LPS
c,d 
IgM              IgG 
1  Summer  F  3y 2m  3 days  -  NI  -  O111  0.58   1.70 
2  Summer  M  8 m  21 days  +  Meat or milk  O26:H11  -  -   - 
3  Spring  M  8 m  12 days  +  NI  -  -  -   - 
4  Winter  F  2y 9m  2 days  +  Meat  -  O111  0.775   3.2 
5  Summer  F  2y 6m  5 days  +  Contact with cattle  -  O157  0.978   1.039 
6  Winter  F  1y 5m  8 days  +  Meat or milk  -  O157  2.90   0.82 
7  Spring  F  6y 3m  5 days  +  NI  -  O157  1.00   0.116 
8  Spring  M  4y 4m  7 days  -  Goat milk  -  O157  3.31   1.50 
9  Fall  F  1y 2m  7 days  -  NI  -  O157  0.472   0.126 
10  Summer  M  2y 3m  1 day  +  Meat or milk  -  O157  0.789   1.004 
11  Summer  F  1y 7m  3 days  -  Cheese  O165:H-  -  -   - 
12  Summer  M  1y 7m  2 days  +  Meat or milk  -  O157  0.462   0.789 
13  Winter  F  3y 10m  5 days  +  Contact with cattle  O157:H7  NT  NT   NT 
a F, female; M, male 
b NI, not identified 
c ELISA absorbance values measured at 492 nm ; NT, not tested; all sera were diluted 1:500 in PBS-Tween.  
d Abs values for positive 1:500 diluted sera controls -LPS O26 : IgM 1.6; IgG 2.1; -LPS O111: IgM 0.58; IgG 1.7; -LPS O157: IgM 2.2; IgG 1.6.  
 
Table 2.  Investigation of Antibodies against LPS O26, O111 and 0157 in 1:500 Diluted Sera of the Control Children by ELISA  
Antibody LPS O26 
a  Antibody LPS O111 
a  Antibody LPS O157 
a 
Control children (n=63) 
IgM IgG IgM IgG IgM IgG 
Mean  (M)  0.057 0.086 0.104 0.279 0.068 0.079 
Standard  Deviation  (SD) 0.087 0.085 0.102 0.272 0.084 0.102 
Cutoff  value  (Cv=M+3xSD)  0.318 0.341 0.410 1.095 0.320 0.385 
a Values are expressed as absorbance at 492 nm and were calculated using the GraphPad Prism 4.0 program. Hemolytic Uremic Syndrome in Pediatric Intensive Care Units in São Paulo, Brazil  The Open Microbiology Journal, 2011, Volume 5    79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Detection of IgM and IgG antibodies against LPS O26 in the serum from patients with HUS and controls by ELISA. Serum samples 
were diluted 1:500 in PBS-Tween, and absorbance values (Abs) were measured at 492 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Detection of. IgM and IgG antibodies against LPS O111 in the serum from patients with HUS and controls by ELISA. Serum  
samples were diluted 1:500 in PBS-Tween, and absorbance values (Abs) were measured at 492 nm. 80    The Open Microbiology Journal, 2011, Volume 5  de Souza et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Detection of IgM and IgG antibodies against LPS O157 in the serum from patients with HUS and controls by ELISA. Serum sam-
ples were diluted 1:500 in PBS-Tween, and absorbance values (Abs) were measured at 492 nm. 
 
stroke during hospitalization. The other exhibited differences 
in walking due to unknown causes, four years after being 
discharged from the hospital. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Representative reaction of patients sera with O111 and 
O157 LPS by immunoblotting. a, serum of patient positive for LPS 
O111 ( case 1 ); b, serum of patient positive for LPS O157 (case 8). 
Lanes: 1, LPS O26; 2, LPS O111; 3, LPS O157. 
Table  3.  Clinic and Laboratory Characteristics of Patients 
with HUS 
Characteristics  Total Case Data and Values  
Clinical 
Diarrhea w/ blood 
Dialysis 
Duration of dialysis 
Hypertension 
Neurological symptoms 
Time of ICU hospitalization 
Time of hospitalization 
Chronic kidney disease  
 
9 patients (69.2%) 
10 patients (76.9%) 
12 days (6–38 days) 
8 patients (61.5%) 
4 patients (30.7%) 
16 days (5–68 days) 
24 days (7–73 days) 
1/10 patients (10%) 
Laboratory results 
Hb (g/dl) 
Platelets per mm
3 
Creatinine (mg/dl) 
Hematuria 
 
4.7 – 10.5
a  
15,000 – 75,000
a 
1.1 – 6.6
b  
5 patients (38.5%) 
a represent the range values of lower limits among patients 
b represent the range values of upper limits among patients 
DISCUSSION 
  The first report of a case of HUS in Brazil was made by 
Penna et al. in 1967 [17]. In 1983, Carvalhaes and Nobrega 
described two cases of post-diarrheal HUS in five-month-old 
twins [18]. Hemolytic Uremic Syndrome in Pediatric Intensive Care Units in São Paulo, Brazil  The Open Microbiology Journal, 2011, Volume 5    81 
  The incidence of HUS in São Paulo is not well docu-
mented and diagnosis may also be underestimated. Data 
from the center for epidemiological surveillance in the State 
of São Paulo (www.cve.saude.sp.gov.br/htm/hidrica/hidri_ 
estat.html) show an incidence of HUS from 1998 to 2007 
that ranges from 0.01 to 0.05 per 100,000 children, but all 
forms of HUS are included. During the period of this study, 
we identified 13 HUS cases associated with diarrhea, and all 
the cases exhibited the characteristics of the illness and 
therefore fit the classic definition of HUS.  
  In Argentina, HUS incidence increased from 8.2, in 
1998, to 13.9/100,000 children under five years of age in 
2005. This was due, in part, to the mandatory notification by 
the national epidemiological surveillance system, established 
in 2000 by the ministry of health [8]. In Germany and Aus-
tria, the incidence is 0.7 and 0.4, respectively, in children 
younger than 15 years of age [19]. In France, the incidence is 
0.7 in children younger than 15 and 1.8 per 100,000 children 
younger than 5 years [20]. In England, the incidence is 1.54 
in children younger than five, while it is 3.4 in Scotland and 
2.33 in Ireland [21]. In Italy, the incidence is 0.2 [22], and 
the reported incidence ranges from 0.2 to 3.4 in the USA [6].  
  Albeit the paucity of data on HUS associated STEC in-
fections in our settings, several STEC serotypes, including 
those principals responsible for HUS in other countries, have 
been isolated from sporadic cases of diarrhea, particularly in 
children, in different regions of Brazil [23-31]. Maybe the 
most important factor is the lack of warning before onset of 
the illness, but physicians should be watchful for cases of 
severe diarrhea, especially in young infants, since 15% of 
STEC infections can develop into HUS [32], and 90% of 
HUS cases are caused by STEC [7, 33].  
  Our study was the first to successfully demonstrate the 
isolation and identification of O157:H7 as well as non-O157 
STEC strains in patients with HUS in Brazil. The first HUS 
case associated with STEC O26:H11 was reported in 2002, 
and the other related to STEC O165:H- was published in 
2007 [34, 35].  
  The detection of serum antibodies to the LPS of E. coli 
O157 and other non-O157 isolates has been reported as an 
effective method to diagnose infections by these organisms 
in HUS patients [14, 16, 33, 36]. In the present study, high 
levels of antibodies to O157 LPS were detected in sera of 
seven patients. These results strongly support evidence of 
infection by O157 isolates in these HUS patients, as preva-
lence of LPS antibodies in the control population was very 
low. On the other hand, a more caution analysis on the asso-
ciation of O111 LPS response and HUS needs to be made. 
This serogroup can be related to different diarrheagenic E. 
coli pathotypes, and has been frequently implicated as agents 
of children diarrhea in São Paulo, Brazil [26, 37]. The high 
titers of IgG to O111 LPS presently identified among the 
control population, and in some HUS patients, certainly re-
flect the important circulation of this serogroup in our set-
tings. However, the higher titers of IgM antibodies to LPS 
O111 identified in two HUS patients, compared to the cutoff 
values obtained among the controls, can suggest an evidence 
of association of this serogroup with the present disease. In 
addition, the specificity of the ELISA results was also con-
firmed by immunoblotting analysis, that showed specific 
O157 and O111 LPS recognition in HUS patients sera. The 
above results confirm that investigation of the specific im-
mune response can improve the diagnosis of STEC infec-
tions especially in HUS patients whose stool cultures are 
negative [14, 16, 33]. 
  Although in the present study the source of infection was 
not traced back, the reported consumption of non-pasteurized 
milk or undercooked meat seemed to be the primary cause of 
infection in the majority of the cases studied, as reported by 
others [6, 8, 38,
 39]. 
  The data presented on the evolution of the illness, dialy-
sis, prognosis, and mortality are similar to those described in 
the literature [8, 19, 20]. Dialysis started during admission 
when the patient presented with oliguria or anuria. The per-
centage of patients on dialysis in Germany, Austria and Aus-
tralia (63%) was closer to our study and greater than that 
from Argentina (59.8%), France (53%) and the USA (55%). 
Our population consisted of patients admitted in the PICU, 
thus the severity of the conditions may justify the greater 
requirement of dialysis (77%) and the development of arte-
rial hypertension (61.5%). However, in the study by Gerber 
et al. [19], only 15% exhibited elevation of blood pressure 
levels.  
  In spite of the low mortality, renal sequelae and chronic 
kidney disease can reach 50% in the long term if all forms of 
HUS are considered. Miliwebsky et al. [40] analyzed cases 
of HUS associated with STEC infections, and reported re-
covery of renal function in 96.2% of the patients and chronic 
kidney disease in only 2.4%, while Cavagnaro et al. [41] 
reported that 11.6% of the patients developed chronic kidney 
disease. Complete recovery of renal function within the first 
months after the illness was exhibited by the majority of our 
patients. Certainly, the prognosis of typical HUS is better, 
and recurrence is rare when compared with other forms of 
the syndrome [32]. The monitoring time for our patients was 
relatively short, and it seems prudent to evaluate renal func-
tion and proteinuria/hematuria for several years after HUS. 
Neurological changes were found in four patients. One of 
them died, and the other two exhibited sequelae, one with 
delayed changes in walking. In studies on the prognosis of 
HUS, data are not presented in relation to neurological se-
quelae or concern over neuro-motor complications. It seems 
important that pediatricians remain vigilant over the changes 
in neurological development in patients affected by HUS. 
  In conclusion, the combined use of microbiologic and 
serologic techniques provided evidence of STEC infection in 
92.3% of the HUS cases studied, and the importance of 
O157 STEC as agents of HUS in São Paulo has not been 
previously highlighted. Albeit the limited number of HUS 
cases identified during the studied period, that may fortu-
nately suggest a relatively low incidence of this syndrome, 
our data strongly indicate that in order to accurately diagnose 
HUS and identify the etiological agent, implements of a sur-
veillance system based on information from nephrologists, 
intensive care specialists and general pediatricians as well as 
on proper laboratory diagnostic procedures are needed. 
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